Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

Clive S. Zent, Charla R. Secreto, Betsy R. LaPlant, Nancy D. Bone, Timothy G. Call, Tait D. Shanafelt, Diane F. Jelinek, Renee C. Tschumper, Neil E. Kay

Research output: Contribution to journal › Article › peer-review

66 Scopus citations

Fingerprint

Dive into the research topics of 'Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab'. Together they form a unique fingerprint.

Medicine & Life Sciences